6533b837fe1ef96bd12a30cd

RESEARCH PRODUCT

Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).

Giovanni ScambiaGabriella FerrandinaBarbara CostantiniAnna FagottiSalvatore Gueli AllettiLucia TortorellaFrancesco FanfaniP.a. MargaritiVito ChianteraFrancesco CosentinoGiuseppe VizzielliValerio Gallotta

subject

0301 basic medicineCancer ResearchChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentfood and beveragesDebulkinglaw.inventionSurgery03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyRandomized controlled triallaw030220 oncology & carcinogenesisMedicineEpithelial ovarian cancerbusinessTumor Load

description

5516Background: Previous randomized multicenter trials determined that neoadjuvant chemotherapy (NACT) was non-inferior to primary debulking surgery (PDS) for both progression-free (PFS) and overal...

https://doi.org/10.1200/jco.2018.36.15_suppl.5516